25 January 2021

Hospital pharmacist and clinical pharmacologist Rob Aarnoutse is appointed as professor in ‘Translation pharmacology of antimicrobial agents, in particular drugs for tuberculosis’ at Radboud University / Radboudumc, starting 16 November 2020.

Rob Aarnoutse will focus his professorship on optimization of drug treatment of tuberculosis (TB), which is the leading cause of death due to an infectious disease worldwide. Each year 1.5 million people die from this disease. His research line extends from preclinical (molecular) pharmacological research to clinical pharmacological work, pharmacokinetic substudies in larger clinical trials, and research on dose optimization in clinical practice (‘molecule to man’). In order to establish this translational and application-oriented research line, he developed a sustainable network with partners in Radboudumc, elsewhere in The Netherlands and Europe, and in lndonesia, Tanzania and South Africa. He coached 12 PhD students as co-supervisor (co-promotor) and is (co)author of 170 international scientific publications.

Rob Aarnoutse studied Pharmacy in Utrecht and was trained as hospital pharmacist at the Albert Schweitzer hospital in Dordrecht, The Netherlands. Since 1999 he has been working at Radboudumc. In 2003 he obtained a PhD title based on his thesis ‘Application of pharmacokinetics to improve antiretroviral treatment’. Besides his research activities, he is actively involved in patient care as hospital pharmacist, dedicated as trainer for hospital pharmacy trainees, and trainer for clinical pharmacology at Radboudumc. Internationally he is member of the chief investigators group of the PanACEA TB research consortium, initiated the leading annual meeting in the TB pharmacology field, and started several international proficiency testing programmes for measurement of drugs in blood.

R.E. Aarnoutse, PharmD PhD, appointed as professor in ‘Translation pharmacology of antimicrobial agents, in particular drugs for tuberculosis’. Appointment on 16 November 2020, for a period of 5 years.

Related news items


KNAW Early Career Award for Martine Hoogman

2 December 2021

Martine Hoogman has been awarded a KNAW Early Career Award. The prize, a sum of 15,000 euros and a work of art, is aimed at researchers in the Netherlands who are at the start of their careers and have innovative, original research ideas.

read more

T-Guard can reset immune system

1 December 2021

For 20 years, the Nijmegen based Radboudumc spin-off company Xenikos has been working on a drug that can reset the immune system. This reset will save lives of seriously ill patients. Now, after years of hard work, the moment of truth has arrived for T-guard.

read more

Thomas van den Heuvel wins Stairway to Impact Award for safer pregnancies using AI Award for safer pregnancies using AI

1 December 2021

Radboudumc researcher Thomas van den Heuvel receives the Stairway to Impact Award from Dutch Research Council NWO. He receives this prize for the development of the BabyChecker, a smartphone application that allows midwives to make ultrasounds during pregnancies.

read more

Villa Joep Research Grant for Radiotherapy & OncoImmunology (ROI) lab

1 December 2021

Renske van den Bijgaart and Gosse Adema from the Radiotherapy & OncoImmunology laboratorium in collaboration with the Prinses Maxima Center received a grant from Villa Joep of 410k Euro.

read more

Participating in cancer research among people with intellectual disabilities

30 November 2021

Thanks to the support of the Maarten van der Weijden Foundation research was carried out into the participation of people with intellectual disabilities in (population) screening for cancer.

read more